These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22488542)

  • 21. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
    Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
    Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Rudramurthy SM; Chakrabarti A; Geertsen E; Mouton JW; Meis JF
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):370-7. PubMed ID: 21937186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp.
    Maesaki S; Iwakawa J; Higashiyama Y; Miyazaki Y; Yanagihara K; Tomono K; Tashiro T; Kohno S
    J Infect Chemother; 2000 Jun; 6(2):101-3. PubMed ID: 11810544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
    Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
    Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE; Wiederhold NP; Klepser ME
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.
    Antachopoulos C; Meletiadis J; Sein T; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2007 Mar; 51(3):881-7. PubMed ID: 17145783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
    Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp.
    Martos AI; Martín-Mazuelos E; Romero A; Serrano C; González T; Almeida C; Puche B; Cantón E; Pemán J; Espinel-Ingroff A
    Diagn Microbiol Infect Dis; 2012 May; 73(1):53-6. PubMed ID: 22480568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus Species.
    Gao L; Ding X; Liu Z; Wu Q; Zeng T; Sun Y
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3813-6. PubMed ID: 26976874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
    Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
    Araujo R; Pina-Vaz C; Rodrigues AG
    Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
    Al-Wathiqi F; Ahmad S; Khan Z
    BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
    Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time-kill studies with micafungin and voriconazole against Candida glabrata intracellularly in human monocyte-derived macrophages and extracellularly in broth.
    Baltch AL; Ritz W; Bopp LH; Michelsen PB; Smith RP
    Diagn Microbiol Infect Dis; 2011 Aug; 70(4):468-74. PubMed ID: 21767703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration.
    Chryssanthou E; Sjölin J
    J Antimicrob Chemother; 2004 Nov; 54(5):940-3. PubMed ID: 15471994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.
    Manavathu EK; Ramesh MS; Baskaran I; Ganesan LT; Chandrasekar PH
    J Antimicrob Chemother; 2004 Feb; 53(2):386-9. PubMed ID: 14729762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
    Heyn K; Tredup A; Salvenmoser S; Müller FM
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.
    Serrano MC; Morilla D; Valverde A; Chávez M; Espinel-Ingroff A; Claro R; Ramírez M; Mazuelos EM
    J Clin Microbiol; 2003 Nov; 41(11):5270-2. PubMed ID: 14605181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.